New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection
83
Citation
15
Reference
10
Related Paper
Citation Trend
Keywords:
Anosmia
Interquartile range
ABSTRACTCovid-19 (coronavirus disease 2019) had spread to the whole world. This kind of virus attacks the human respiratory system, and it caused death. In other words, there were many symptoms of Covid-19, which attacks the respiratory system. One of the symptoms was anosmia or smell disorder. This research might provide information about the anosmia in Covid-19 patients. This study aimed to investigate and present a series about anosmia and Covid-19 in Yogyakarta on June 2020. Three cases from three patients of RT-PCR-confirmed SARS-CoV-2-infected patients diagnosed with smell disorder were presented, starting from the symptom until the patients were getting treatments. This research also explained anosmia as one of the symptoms of Covid-19. Anosmia or losing olfactory function or smell disorder which could distract people’s healthy. Then, in this situation, it could be one of the symptoms of Covid-19. Keywords : anosmia, smell disorder, covid-19Corresponding Author : rizkafakhriani@gmail.com
Anosmia
2019-20 coronavirus outbreak
Cite
Citations (0)
The occurrence of anosmia, the loss or change in sense of smell, is one of the most common symptoms of COVID-19 experienced by almost 53% of those affected. Several hypotheses explain the mechanism of anosmia in patients suffering from COVID-19. This study aims to review the related mechanisms and answer the questions regarding COVID-19-related anosmia as well as propose a new strategy for treatment of long-term anosmia as a result of COVID-19 infection. This paper covers all of the studies investigating olfactory disorders following COVID-19 infection and explains the possible reasons for the correlated anosmia, including olfactory cleft syndrome, local inflammation in the nasal epithelium, early apoptosis of olfactory cells, changes in olfactory cilia and odor transmission, damage to microglial cells, effect on olfactory bulbs, epithelial olfactory injury, and impairment of olfactory neurons and stem cells. The key questions that arise in this field have been discussed, such as why prevalent anosmia is varied among the age categories and among sexes and the correlation of anosmia with mild or severe COVID-19 infection. The angiotensin-converting enzyme 2 receptor is a significant player in the mechanism of anosmia in COVID-19 patients. Based on current studies, a novel approach to treat long-COVID-19 with ongoing anosmia has been proposed. The fields of smart drug delivery, tissue engineering, and cell therapy provide a hypothesized strategy that can minimize the side effects of current treatments and support efficient recovery of the olfactory system.
Anosmia
Olfactory Receptor Cell
Cite
Citations (85)
Abstract Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for a pandemic affecting millions of people worldwide. Apart from the extreme global economic impact, the pandemic will likely have a lasting impact through long-term sequelae not yet fully understood. Fully understanding the mechanisms driving the various symptoms and sequelae of SARS-CoV-2 infection will allow for the eventual development of therapeutics to prevent or treat such life-altering symptoms. In this study, we developed a behavioral test of anosmia in SARS-CoV-2-infected hamsters. We find a moderately strong correlation between the level of anosmia and the score of histological damage within the olfactory epithelium. We also find a moderately strong correlation between the level of anosmia and the thickness of the olfactory epithelium, previously demonstrated to be severely damaged upon infection. Thus, this food-searching behavioral test can act as a simple and effective screening method in a hamster model for various therapeutics for SARS-CoV-2-related anosmia.
Anosmia
Pandemic
Cite
Citations (0)
This study aimed to determine the frequency of SARS-CoV-2 RNA in serum and its association with the clinical severity of COVID-19. This retrospective cohort study performed at Toyama University Hospital included consecutive patients with confirmed COVID-19. The prevalence of SARS-CoV-2 RNAemia and the strength of its association with clinical severity variables were examined. Fifty-six patients were included in this study. RNAemia was detected in 19.6% (11/56) patients on admission, and subsequently in 1.0% (1/25), 50.0% (6/12), and 100.0% (4/4) moderate, severe, and critically ill patients, respectively. Patients with RNAemia required more frequent oxygen supplementation (90.0% vs. 13.3%), ICU admission (81.8% vs. 6.7%), and invasive mechanical ventilation (27.3% vs. 0.0%). Among patients with RNAemia, the median viral loads of nasopharyngeal (NP) swabs that were collected around the same time as the serum sample were significantly higher in critically ill (5.4 log
2019-20 coronavirus outbreak
Betacoronavirus
Pandemic
Cite
Citations (45)
Anosmia
Hyposmia
Dysgeusia
Cite
Citations (49)
Abstract Background There is solid evidence that olfactory dysfunction (OD) can present in COVID-19 patients. Anosmia can be the only presentation or can be accompanied by other symptoms of COVID-19. Multiple cross-sectional studies have demonstrated that the incidence rate of olfactory dysfunction is high in COVID-19 patients with good prognosis. The aim of our study is to investigate the presence of OD with the radiologic and laboratory findings among COVID-19 positive patients. Results There was statistical significance in clinical severity between anosmia and non-anosmia group ( P value 0.000) denoting that anosmia sign mostly occur in mild COVID. Also, there was significance in D dimer between two groups ( P value 0.044) denoting that D dimer could be a sign of clinical severity and it is usually not elevated in anosmia. All anosmia group had normal CT chest denoting that it is a mild form of COVID-19. Conclusions Olfactory dysfunction (OD) is an imminent sign of COVID-19 patient, which can be presented as a sole symptom or with other symptoms. As anosmia could be the sole clinical presentation of COVID-19 patients without any other significant signs and so otolaryngologists should be aware of this presentation in COVID-19 diagnosis.
Anosmia
Presentation (obstetrics)
Clinical Significance
Cite
Citations (3)
Objective Olfactory dysfunction (OD)—hyposmia or anosmia—is a symptom of coronavirus disease 2019 (COVID‐19), caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). We sought to better determine prevalence, severity, and timing of OD in COVID‐19 relative to other sinonasal and pulmonary symptoms. Study Design Prospective, cross‐sectional. Setting Regional/cantonal hospital. Subjects In total, 103 patients diagnosed with COVID‐19 with reverse transcription polymerase chain reaction (RT‐PCR)–based testing. Methods All patients testing positive for COVID‐19 at Kantonsspital Aarau over a 6‐week period were approached. Timing and severity (at its worst, on scale of 0 [none], 1 [mild], 2 [moderate], and 3 [severe]) of OD, loss of taste, nasal obstruction, rhinorrhea/mucus production, fever, cough and shortness of breath (SOB) were assessed for each patient. Results Prevalence of OD was 61.2%, and severity of OD was strongly correlated with severity of loss of taste experienced (ρ = 0.87, P <. 001). OD was experienced on the first day of COVID‐19 by 8.7% and overall occurred at median infection day 3 (mean, 3.4; range, 0‐12). Most experiencing OD reported anosmia, and mean severity of all with OD was moderate to severe (mean [SD], 2.7 [0.6]). Nasal obstruction (49.5%) and rhinorrhea (35.0%) were frequently reported but not correlated with OD. SOB was more severe in patients with OD. OD was associated negatively with older age (OR, 0.96; 95% CI, 0.93‐0.99; P =. 007) and positively with female sex (OR, 2.46; 95% CI, 0.98‐6.19; P =. 056). Conclusions OD is highly prevalent during COVID‐19, occurring early and severely, often in conjunction with loss of taste. OD is associated negatively with older age and positively with female sex. Patients with OD may also experience more severe SOB.
Anosmia
Hyposmia
Cite
Citations (258)
Introduction Anosmia is one of the common symptoms of COVID-19, the link between severity of chest infection and anosmia was investigated by few studies. Objectives To find an association between anosmia and severity of chest infection. Methods An analysis of patients admitted to isolation hospital of our university with confirmed polymerase chain reaction positive testing for COVID-19, between March 2021 until September 2021. We called all patients who reported anosmia during their time of illness and asked them about anosmia. We examined their chest CT. A statistical analysis was done. Results A total of 140 patients completed the study; 65% were female and 56.4% had complete anosmia. Anosmia was significantly associated with loss of taste. Smell returned in 92.5% of anosmic patients. Duration of smell loss was ∼ 2 weeks in 40.5%. The most common symptoms associated with anosmia were running nose, sore throat, fever, and cough. Loss of smell was significantly associated with mild chest disease. 73.4% of anosmic patients had mild chest infection, 21.5% of them had moderate infection, and 5.1% had severe chest infection. Conclusion The pattern of anosmia in COVID-19 patients has some common similarities in general; the way it starts, the associated symptoms, the time until smell returns and, the most important, the severity of chest infection. As anosmia is significantly associated with mild chest infection. the presence of anosmia could be an independent predictor of good COVID-19 outcome as reflected by a lower disease severity and less frequent ICU admissions.
Anosmia
Sore throat
Cite
Citations (6)
Based on observations described in our letter, we can draw the following conclusions: (1) anosmia must imperatively be added to the list of specific symptoms of COVID-19 infection, (2) anosmia can serve as a free and specific diagnostic tool for developing countries currently affected by the pandemic, (3) the mechanisms of COVID-19 anosmia seem not to directly involve nasal obstruction but rather seem to be related to damage the olfactory neuroepithelium.
Anosmia
2019-20 coronavirus outbreak
Pandemic
Cite
Citations (20)
A significant proportion of people infected with SARS-CoV-2 report a new onset of smell or taste loss. The duration of the chemosensory impairment and predictive factors of recovery are still unclear. We aimed to investigate the prevalence, temporal course and recovery predictors in patients who suffered from varying disease severity. Consecutive adult patients diagnosed to be infected with SARS-CoV-2 via reverse-transcription–polymerase chain reaction (RT-PCR) at two coronavirus disease-2019 (COVID-19) Reference Hospitals were contacted to complete a survey reporting chemosensory loss, severity, timing and duration, nasal symptoms, smoking, allergic rhinitis, chronic rhinosinusitis, comorbidities and COVID-19 severity. In a cross-sectional study, we contacted 182 patients and 150 responded. Excluding the critically ill patients, 38% reported gustatory and 41% olfactory impairment (74% severe/anosmia). Most of the patients (88%) recovered their sense of smell by two months (median: 11.5 days; IQR: 13.3). For 23%, the olfactory loss lasted longer than a month. There were no significant differences in the prevalence and duration of chemosensory loss between groups of varying COVID-19 severity, and sexes (all p > 0.05). Moderate hyposmia resolved quicker than more severe loss (p = 0.04). Smell and taste loss are highly prevalent in COVID-19. Most patients recover fast, but nearly one out of ten have not recovered in two months.
Anosmia
Hyposmia
Taste disorder
Cite
Citations (67)